Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, PEG-MGF is used experimentally to enhance muscle repair and hypertrophy after mechanical overload or injury by stimulating satellite-cell activation and protein synthesis6373138.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, PEG-MGF is a poly(ethylene glycol)-conjugated form of Mechano Growth Factor (IGF-1Ec splice variant) comprising the 24-aa C-terminal E-peptide of IGF-1, designed to extend half-life while activating IGF-1 receptor–mediated anabolic signaling in muscle satellite cells637322138.
Liraglutide
GCG
PEG-MGF
IGF1
Liraglutide and PEG-MGF are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Liraglutide is more often discussed in the realm of Metabolic and endocrine, whereas PEG-MGF is more often associated with the realm of Musculoskeletal health and Cardiovascular health. Their biological logic is quite different: Liraglutide is a receptor agonist and a hormone analog, whereas PEG-MGF is a growth factor mimetic and a signaling modulator. Both are synthetic in origin and their development context also differs, with Liraglutide approved while PEG-MGF is in Preclinical development. Liraglutide carries palmitoylation features, while PEG-MGF instead reflects pegylation changes, while their sequence patterns also diverge, with Liraglutide showing alpha-helical domain features and PEG-MGF showing protein-mimetic sequence features.